NCT05862064 · ClinicalTrials.gov record · last posted 2025-07-16
A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer
StatusRecruiting
PhasePhase 3
Started2023-06-01
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 16, 2025 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
This review will evaluate the efficacy and safety of SHR1210 (Camrelizumab) and antivascular drug(Famitinib) in combination with anthracyclines/taxane-based adjuvant chemotherapy (carrelizumab + FAM + EC-P) compared with conventional chemotherapy regimens (dose-intensive epirubicin and cyclophosphamide, sequential paclitaxel, or EC-P) in patients with early-stage high-risk TNBC.
Amendment record
2 amendments on the ClinicalTrials.gov record
This ClinicalTrials.gov record has been amended 2 times since 2023-05-08; most recent amendment 2025-07-12. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history.
See every version on ClinicalTrials.gov ↗
2024-03-21
Status change Not Yet Recruiting→Recruitingv1
| NCT Number |
NCT05862064 |
| Lead Sponsor |
Fudan University
|
| Conditions |
TNBC - Triple-Negative Breast Cancer |
| Enrollment |
606 participants |
| Start Date |
2023-06-01 |
| Primary Completion |
2026-07-01 (estimated) |
| Study Completion |
2028-07-01 (estimated) |
| Updated on ClinicalTrials.gov |
2025-07-16 |